GRAIL, Inc. GRAL R2K
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 38.4% over 5 years.
- Profit CAGR of 30.8% over 5 years.
CONS
- Trading 38.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GRAL GRAIL, Inc. R2K | 71.68 | - | $3.08B | - | -18.79% | -16.09% | 38.37% | 30.81% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Apr 2023 | Jun 2023 | Jul 2023 | Oct 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 22.41M | - | 20.72M | 26.72M | 31.97M | - | - | 31.84M | 35.54M | 36.19M | 43.60M | 40.78M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 51.77M | 53.32M | 49.93M | 54.73M | 55.09M |
| Gross Profit | - | - | - | - | - | - | - | - | - | -19.93M | -17.77M | -13.73M | -11.14M | -14.31M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 133.68M | 113.08M | 111.56M | 113.28M | 121.46M |
| Operating Income | - | - | -204.37M | - | -912.39M | -227.42M | -1.64B | - | - | -153.61M | -130.85M | -125.29M | -124.41M | -135.76M |
| EBITDA | - | - | - | - | - | - | - | - | - | -114.33M | -91.68M | -86.31M | -85.50M | -96.97M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | -146.41M | -152.86M | -118.72M | -116.52M | -127.52M |
| Tax Provision | - | - | - | - | - | - | - | - | - | -40.20M | -38.87M | -29.74M | -17.34M | -34.34M |
| Net Income | -193.67M | -193.67M | -193.04M | -193.04M | -891.45M | -218.91M | -1.59B | - | - | -106.21M | -113.98M | -88.98M | -99.18M | -93.19M |
| Diluted EPS | - | - | -6.22 | - | -28.71 | -7.05 | -51.06 | - | - | -3.10 | -3.18 | -2.46 | -2.44 | -2.29 |
| R&D Expense | - | - | - | - | - | 101.62M | 94.20M | 78.23M | - | 53.62M | 46.63M | 48.65M | - | 48.02M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.55M | 55.55M | 93.11M | 125.59M | 147.17M |
| Cost of Revenue | 172.00M | - | 188.72M | 203.62M | 209.75M |
| Gross Profit | -116.45M | - | -95.61M | -78.02M | -62.57M |
| Operating Expenses | 626.01M | - | 701.30M | 690.20M | 471.59M |
| Operating Income | -742.46M | -5.44B | -796.92M | -768.22M | -534.16M |
| EBITDA | -587.70M | - | -638.22M | -610.17M | -377.82M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | -5.44B | - | -1.51B | -2.16B | -534.50M |
| Tax Provision | -42.29M | - | -41.95M | -135.36M | -126.15M |
| Net Income | -5.40B | -5.40B | -1.47B | -2.03B | -408.35M |
| Diluted EPS | -173.89 | -173.89 | -47.21 | -63.54 | -11.11 |
| R&D Expense | - | 329.58M | 338.75M | 322.38M | 195.79M |
Compounded Sales Growth
| 5 Years: | 38.37% |
| 1 Year: | 28.10% |
Compounded Profit Growth
| 5 Years: | 30.81% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +86.62% |
| 6 Months: | -33.44% |
| 3 Months: | +34.66% |
| 1 Month: | +44.25% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | 4.94B | - | 3.91B | 2.98B | 2.92B |
| Current Assets | 295.63M | - | 156.06M | 819.86M | 953.85M |
| Cash & Equivalents | 241.60M | 241.60M | 97.29M | 214.23M | 249.73M |
| Inventory | 19.75M | - | 21.70M | 18.63M | 16.02M |
| Receivables | 15.35M | - | 16.94M | 20.31M | 18.30M |
| Total Liabilities | 291.82M | - | 267.63M | 479.90M | 344.15M |
| Current Liabilities | 134.94M | - | 163.61M | 76.92M | 79.67M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | 96.01M | - | 84.41M | 68.14M | 54.86M |
| Total Equity | 0 | - | 0 | 2.50B | 2.58B |
| Shares Outstanding | 31.10M | - | 31.10M | 33.89M | 40.33M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -561.31M | -561.31M | -595.80M | -577.16M | -299.01M |
| Investing Cash Flow | -22.86M | -22.86M | -12.89M | -551.01M | -85.05M |
| Financing Cash Flow | 604.82M | 604.82M | 463.77M | 1.24B | 423.32M |
| Capital Expenditure | -22.86M | -22.86M | -12.89M | -5.21M | -909.00K |
| Free Cash Flow | -584.17M | -584.17M | -608.69M | -582.36M | -299.92M |
| Net Change in Cash | 20.64M | - | -144.92M | 116.13M | 39.27M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | -209.6% | - | -102.7% | -62.1% | -42.5% |
| Operating Margin % | -1,336.6% | -9,798.2% | -855.9% | -611.7% | -363.0% |
| Net Margin % | -9,719.3% | -9,719.3% | -1,574.2% | -1,613.9% | -277.5% |
| ROE % | - | - | - | -81.0% | -15.8% |
| ROCE % | -15.5% | - | -21.2% | -26.4% | -18.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Baker Bros. Advisors, LP | 9.39% | 4.03M | $288.77M |
| 2 | Farallon Capital Management LLC | 7.58% | 3.25M | $233.22M |
| 3 | Blackrock Inc. | 6.92% | 2.97M | $212.78M |
| 4 | State Street Corporation | 4.41% | 1.89M | $135.61M |
| 5 | Primecap Management Company | 4.30% | 1.84M | $132.16M |
| 6 | Deep Track Capital, Lp | 4.01% | 1.72M | $123.49M |
| 7 | Sessa Capital IM, L.P. | 4.01% | 1.72M | $123.24M |
| 8 | Morgan Stanley | 3.80% | 1.63M | $117.00M |
| 9 | Vanguard Capital Management LLC | 3.56% | 1.53M | $109.46M |
| 10 | Arbiter Partners Capital Management LLC | 2.41% | 1.03M | $74.16M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GRAL